Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716857 | 0.84 | CA1 (0.35) | ALDH1A1PTGS1TDP1MAPTKDM4E | |
| SCHEMBL4097608 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1MAPT | |
| SCHEMBL177124 | 0.80 | TSHR (0.46) | ALDH1A1ADRA2BPTGS1TDP1MAPT | |
| SCHEMBL31451612 | 0.76 | CA2 (0.48) | ALDH1A1TDP1MAPTKDM4ELMNA | |
| SCHEMBL18037101 | 0.76 | CA2 (0.48) | ALDH1A1TDP1MAPTKDM4ELMNA | |
| SCHEMBL28098932 | 0.75 | ALDH1A1 (0.54) | ALDH1A1ADRA2BPTGS1TDP1MAPT | |
| SCHEMBL27826164 | 0.75 | PNMT (0.43) | ALDH1A1KDM4ELMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10063427 | 0.75 | MAPT (0.38) | ALDH1A1TDP1MAPTKDM4ECYP2C9 | |
| SCHEMBL18037108 | 0.74 | SMN1; SMN2 (0.44) | ALDH1A1TDP1MAPTLMNARECQL | |
| SCHEMBL3363981 | 0.74 | GRM4 (0.39) | ALDH1A1ADRA2BMAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105163768-B | Antimicrobial aquogel polymer | 开尔弗森2200有限公司 | 2018-04-13 | — | — | CN | claimed |
| CN-105163768-A | Antimicrobial hydrogel polymers | CAREFUSION 2200 INC | 2015-12-16 | — | — | CN | claimed |
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116870016-A | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-115785154-A | Heteroaromatic ring compounds and medical use thereof | 希格生科（深圳）有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-105163768-B | Antimicrobial aquogel polymer | 开尔弗森2200有限公司 | 2018-04-13 | — | — | CN | disclosed |
| US-9920083-B2 | Image recording paper medium and image recording method | FUJIFILM CORPORATION (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20160250866-A1 | IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| CN-105163768-A | Antimicrobial hydrogel polymers | CAREFUSION 2200 INC | 2015-12-16 | — | — | CN | disclosed |
| CN-101410120-A | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | CN | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | ALDH1A1 4028/4885ADRA2B 3208/4885PTGS1 993/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | ALDH1A1 3467/4885ADRA2B 3071/4885PTGS1 6/4885 |
| US-20160250866-A1 | IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD | PHOSPHO1, ITPR2, PPIP5K2 | ALDH1A1 4176/4885ADRA2B 2494/4885PTGS1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.